Dreicer
Medical Oncology · University of Virginia Physicians Group
Credentials: · · ·
History
Indiana University Medical Center
- 1983
University of Texas Health Sciences Center
Research
Sipuleucel-T immunotherapy for castration-resistant prostate cancer
New England Journal of Medicine · 2010 · 4,436 citations
The Lancet · 2016 · 2,972 citations
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
New England Journal of Medicine · 2015 · 2,355 citations
53 papers · 13 as a fellow
31 papers
- EK
27 papers
- RB
19 papers
18 papers
- MC
18 papers
- GW
17 papers
- TM
15 papers
Grants
- 1997–2022
University of Virginia Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $558.5K · University of Virginia
- 2014–2019
CWRU Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
National Cancer Institute · U10
PI · $1.4M · Case Western Reserve University
Clinical trials
- 2007–2012
CC-4047 in Treating Patients With Advanced Solid Tumors That Did Not Respond to Treatment
Principal investigator · Completed · Phase 1
Case Comprehensive Cancer Center
- 2006–2010
GM-CSF in Treating Patients With Relapsed Prostate Cancer
Principal investigator · Completed · Phase 2
Case Comprehensive Cancer Center
- 2005–2008
Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium
Principal investigator · Terminated · Phase 2
National Cancer Institute (NCI)
- 2005–2012
Lenalidomide and GM-CSF in Treating Patients With Prostate Cancer
Principal investigator · Completed · Phase 1, Phase 2
Robert Dreicer MD